Navigation Links
Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes

MOUNTAIN VIEW, Calif. Nov. 5, 2009 Complete Genomics, a third-generation human genome sequencing company, today announced publication of a report in the journal Science describing its proprietary DNA sequencing platform, including analysis of sequence data from three complete human genomes. The consumables cost for these three genomes sequenced on the proof-of-principle genomic DNA nanoarrays ranged from $8,005 for 87x coverage to $1,726 for 45x coverage for the samples described in this report.

"We've demonstrated that it's possible to accurately and affordably sequence and detect variants across entire human genomes," said Cliff Reid, chairman, president and CEO of Complete Genomics. "This high-quality, cost-effective approach to genome sequencing will allow researchers to study complete genomes from hundreds of patients with a disease to advance the understanding of the genetic causes of that disease, with an end to preventing and treating common human ailments."

The manuscript, titled, "Human Genome Sequencing Using Unchained Base Reads on Self‐assembling DNA Nanoarrays," describes the methodology used to sequence cell lines derived from two individuals previously characterized by the International HapMap project. These included a Caucasian male of European descent (NA07022) and a Yoruban female (NA19240). In addition, researchers sequenced lymphoblast DNA from a Caucasian male sample (NA20431) obtained from the Personal Genome Project (

Complete Genomics' proprietary platform enables efficient imaging, while requiring low reagent consumption, through its combinatorial probe anchor ligation (cPAL) chemistry and its use of patterned genomic DNA nanoarrays. With this approach, Complete Genomics' scientists generated high-quality diploid base calls in as much as 95 percent of the genomes sequenced, identifying 3.2 million to 4.5 million sequence variants per genome processed.

Detailed validation of one genome dataset demonstrates a sequence accuracy of just one false variant per 100 kilobases, a remarkably low error rate, particularly for such an affordable technology.

Patterned genomic DNA nanoarrays and 70-base, unchained sequence reads are unique technical achievements. The company's new patterned genomic DNA nanoarrays, which achieve a record high density of 2.85 billion spots per slide at 0.7 micron pitch, will enable Complete Genomics to sequence 10,000 human genomes in 2010.


Contact: Andrea Long
Complete Genomics

Related biology technology :

1. Dendreon Completes Submission of Biologics License Application for PROVENGE
2. U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma
3. Cardium Completes $6.0 Million Registered Direct Offering
4. Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
5. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
6. Stemedica Completes Meeting with the FDA
7. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
8. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
9. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
10. Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
11. ePDF is Happy to Announce that ePDF has Completed its First Relaunch, and has Come Out as a Beta
Post Your Comments:
Related Image:
Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes
(Date:10/13/2015)... , Oct. 13 2015 Research and ... "US & Europe Markets for Bone Morphogenetic Protein ... to their offering. --> ... that induce the formation of bone after a fracture. ... embryonic development in the formation of the skeleton. There ...
(Date:10/13/2015)... FLORHAM PARK, N.J. and SAN ... Corporation (BASF) and Mast Therapeutics, Inc. have agreed to ... 188.  Currently, excipient-grade poloxamer 188 NF, marketed by BASF ... polymer used in a variety of pharmaceutical and biological ... production. Poloxamer 188 is the starting material for Mast,s ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... distributor of automation systems, material handling solutions and components, is opening its latest ... near State Street, the facility is Exotic’s second major expansion in Metropolitan Detroit ...
(Date:10/13/2015)... the United States , ... represents about 14% of all new cases of kidney cancer.   ... Canada and Europe .  PRCC represents ... --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces ... AB (publ) ("AstraZeneca") have completed enrolment in a global Phase II ...
Breaking Biology Technology:
(Date:9/30/2015)... -- With nearly 300,000 Americans living with spinal cord injuries ... reach 12,500 annually, the role of Independent Living Centers ... Living (SCRS-IL) is increasingly important. SCRS-IL is one ... opening doors to independence for individuals with SCIs by ... technology services and education. "In serving people ...
(Date:9/30/2015)...  The global glucose monitoring device and diabetes management market ... new report on the industry from Kalorama Information. Sales in the ... followed by continuous glucose monitoring and sensor segment, according to ... these products in its latest report, The Global Glucose ... , ...
(Date:9/29/2015)...  iDAvatars is excited to be named one of the ... The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a demo ... "It is both an honor and a privilege ... to market the cognitive power of IBM Watson in our ...
Breaking Biology News(10 mins):